MercoPress. South Atlantic News Agency

Brazil launches vaccination campaign, but many supply problems persist

Minutes after health agency Anvisa approved the Sinovac vaccine on Sunday, Monica Calazans, a nurse in Sao Paulo, became the first person to be inoculated

Brazil launched on Monday the national inoculation program with China's Sinovac Biotech vaccine, but so far it includes five of the country's 26 states. After weeks of setbacks, many Brazilians cheered the first wave of inoculations, from bustling clinics in Sao Paulo to a spectacular shot planned at the foot of the Christ Redeemer statue overlooking Rio de Janeiro.

The Health Ministry gave states the green light to start immunizing at 5 p.m. (2000 GMT). Although some began administering shots before that, the majority of Brazil’s 26 states had yet to receive vaccine shipments as of Monday evening, delaying the start of vaccinations for the elderly and frontline health workers.

Minutes after federal health agency Anvisa approved the Sinovac vaccine on Sunday, Monica Calazans, a 54-year-old nurse in Sao Paulo, became the first person to be inoculated in the country, as Sao Paulo Governor Joao Doria looked on.

President Jair Bolsonaro, a COVID-19 skeptic who has refused to take a vaccine himself, had faced fierce criticism for the lack of immunization in Brazil, which has lost more than 210,000 lives to COVID-19 – the pandemic’s worst death toll outside the United States.

On Sunday, Anvisa approved emergency use of the Sinovac vaccine and one from AstraZeneca Plc, although a plan to get 2 million doses of the AstraZeneca vaccine was hamstrung by a lack of export approval from India.

That was one of several hurdles threatening to slow Brazil’s already lagging immunization efforts, as local manufacturing partners for both vaccine makers wait on active ingredients from abroad in order to fill and finish doses for distribution.

The Butantan Institute run by Sao Paulo state needs another shipment of Sinovac’s ingredients by the end of the month in order to hit its target of 46 million doses by April, the head of the institute told a news conference.

The federally-funded Fiocruz biomedical center in Rio de Janeiro is still awaiting its first shipment of ingredients for AstraZeneca’s vaccine, pending Chinese export approval.

With information from Reuters